Literature DB >> 17494969

A global comparison regarding patient access to cancer drugs.

B Jönsson1, N Wilking.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17494969     DOI： 10.1093/annonc/mdm095

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  The role of funding and policies on innovation in cancer drug development.

Authors:  P Kanavos; R Sullivan; G Lewison; W Schurer; S Eckhouse; Z Vlachopioti
Journal:  Ecancermedicalscience       Date:  2010-02-03

Review 2.  Advances in cancer therapeutics and patient access to new drugs.

Authors:  George Dranitsaris; Ilse Truter; Martie S Lubbe; Eitan Amir; William Evans
Journal:  Pharmacoeconomics       Date:  2011-03       Impact factor: 4.981

3.  Should be NICE have a Spanish NICE?

Authors:  J Feliu; E Espinosa
Journal:  Clin Transl Oncol       Date:  2013-06-06       Impact factor: 3.405

4.  Relative effectiveness and the European pharmaceutical market.

Authors:  Bengt Jönsson
Journal:  Eur J Health Econ       Date:  2011-04

5.  The economic impact of the transition from branded to generic oncology drugs.

Authors:  W Y Cheung; E A Kornelsen; N Mittmann; N B Leighl; M Cheung; K K Chan; P A Bradbury; R C H Ng; B E Chen; K Ding; J L Pater; D Tu; A E Hay
Journal:  Curr Oncol       Date:  2019-04-01       Impact factor: 3.677

6.  Efficient allocation of novel agents in multiple myeloma: a work in progress.

Authors:  Jennifer G Gaultney; Carin A Uyl-de Groot
Journal:  Oncologist       Date:  2013-01-08

7.  Evolution of costs of cancer drugs in a Portuguese hospital.

Authors:  Vânia Peixoto; Ana Luísa Faria; Márcia Gonçalves; Joana Macedo; Sónia Rego; Emilio Macías; Aldiro Magano; Márcia Loureiro; António Araújo
Journal:  World J Clin Oncol       Date:  2014-05-10

8.  Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

Authors:  Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman
Journal:  Lancet       Date:  2014-11-26       Impact factor: 79.321

Review 9.  When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.

Authors:  Dan Greenberg; Craig Earle; Chi-Hui Fang; Adi Eldar-Lissai; Peter J Neumann
Journal:  J Natl Cancer Inst       Date:  2010-01-07       Impact factor: 13.506

Review 10.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients.

Authors:  Muireann T Kelleher; Gilbert Fruhwirth; Gargi Patel; Enyinnaya Ofo; Frederic Festy; Paul R Barber; Simon M Ameer-Beg; Borivoj Vojnovic; Cheryl Gillett; Anthony Coolen; György Kéri; Paul A Ellis; Tony Ng
Journal:  Target Oncol       Date:  2009-09-16       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.